Business Context and Reporting Period
This Form 8-K filing by Zura Bio Ltd (ZURA) covers events occurring on January 20, 2026, and January 21, 2026. The report details a significant management transition involving the resignation of the Chief Executive Officer (CEO), the appointment of a new CEO, and changes to the Board of Directors. The company is incorporated in the Cayman Islands and trades on The Nasdaq Stock Market.
Key Financial Metrics and Compensation
This filing does not contain financial performance data such as revenue, profit, cash flow, or debt levels. The financial information provided is limited to executive compensation and severance arrangements:
- Outgoing CEO Severance: Robert Lisicki is eligible for transition compensation of $72,000 (annualized) through March 31, 2026, followed by a lump-sum severance equal to twelve months of his base salary (less transition compensation).
- New CEO Compensation: Dr. Sandeep Kulkarni will receive an annual base salary of $655,000 and a discretionary annual cash bonus with a target of 55% of base salary.
- Director Compensation: New director Parvinder Thiara will receive an annual cash retainer of $40,000 (prorated) and stock options valued up to $200,000.
Material Changes
The filing reports the following material changes in corporate governance and leadership:
- CEO Resignation: Robert Lisicki resigned as CEO and Board member effective January 21, 2026, following a medical leave of absence that began in October 2025.
- CEO Appointment: Dr. Sandeep Kulkarni, a current director, was appointed CEO and principal executive officer effective January 21, 2026.
- Interim Role Conclusion: Kim Davis stepped down as interim CEO, returning to her roles as Chief Operating Officer, Chief Legal Officer, and Corporate Secretary.
- Board Changes: Parvinder Thiara was appointed as a director effective January 23, 2026. Jennifer Jarrett replaced Dr. Kulkarni as a member of the audit committee.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or operational outlook. However, it outlines specific conditions tied to executive equity awards that reflect future performance expectations:
- Performance Vesting: Dr. Kulkarni's performance option award (505,881 shares) vests only upon achieving two goals: (a) completion of an equity raise above a specified amount by a specified date, and (b) the stock price meeting a specified volume-weighted average over 30 consecutive trading days prior to December 31, 2030.
- Related Party Transaction: A letter agreement exists between the Company and Athanor Capital (managed by new director Parvinder Thiara), previously disclosed on January 2, 2026.
- Contingencies: All severance payments to Mr. Lisicki are contingent upon the effectiveness of the Separation Agreement and his compliance with its terms, including a release of claims.
Investor Verification Checklist
- Verify the specific equity raise amount and deadline required for Dr. Kulkarni's performance option vesting.
- Review the full text of the Separation Agreement (Exhibit 10.1) for details on Mr. Lisicki's base salary to calculate the exact lump-sum severance.
- Examine the letter agreement with Athanor Capital (referenced in the Related Party Transactions section) to understand the nature of the relationship with the new director.
- Confirm the status of the company's cash runway given the upcoming equity raise requirement mentioned in the CEO's performance metrics.